Resources

Suil Vision has launched with £500k of seed funding from Cancer Research Horizons. The new company aims to create a market-ready biological data visualisation tool for researchers.

Arecor presents data from trial of ultra-concentrated, ultra-rapid acting insulin in overweight and obese people.

Twenty-three companies will benefit from a share of £12 million from the Innovate UK Cancer Therapeutics programme. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing unmet medical needs for treating childhood and young persons’ cancers.

Innovate UK Phage Innovation Network has published a report entitled: Developing and delivering phage-based technologies in the UK.

PIR International is pleased to announce the appointment of Dieter Weinand as Non-Executive Chair at Anaveon.

With an initial investment of £28 million in resource and funding from LifeArc and Cancer Research UK, the consortium will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise to progress innovations for children and young people’s cancers.

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced the launch of its proprietary CiliaBeat software and application in a Lung Ciliary Beat Frequency Analysis assay.

Myricx Bio joins Kadans’ pioneering innovation centre in Canary Wharf, providing the facilities for its future expansion and pipeline progression.

Coulter Partners recently partnered with Compass Pathways (Nasdaq: CMPS) (“Compass”) and is pleased to announce the placement of Gino Santini as Chairman of its Board of Directors and Michael Gold, MD as Chief Research and Development Officer.

The highly anticipated Health Innovation Hub (HiH) in Glasgow has reached a significant milestone with the completion of the building’s primary structure.

Accession Therapeutics Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment has filed a Clinical Trial Application (CTA) with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This is the first clinical trial showcasing the company’s TROCEPT-01 lead program and will enrol patients with a variety of solid tumour carcinomas including non-small cell lung, bladder, pancreatic, head and neck, cholangiocarcinoma and endometrial cancers.

ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult (MDC), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology.

Coulter Partners recently partnered with Tristel plc and is pleased to announce the placement of Matthew Sassone as Chief Executive Officer and to the Tristel Board, with effect from 2 September 2024.

Company secures additional financing to advance clinical programmes in Immuno-Oncology and Inflammatory bowel disease through to data readout

Mestag was awarded a “Transforming Cancer Therapeutics” grant of £1.5/$1.9 million from Innovate UK to accelerate MST-0300, which is designed to induce tertiary lymphoid structures (TLS) in solid tumors, as an exciting and novel therapeutic approach.

The convergence of science and tech is reshaping key UK markets, with Cambridge and Oxford leading the charge. Download the Bidwells' databooks for detailed insights.